Novo Nordisk
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.About NVO
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.
NVO Key Statistics
NVO News
Shares of several names in the obesity-drug space, including Viking Therapeutics (VKTX), Terns Pharmaceuticals (TERN), and Structure Therapeutics (GPCR), are mo...
Wall Street has labeled the airline industry as a surprising winner from the growing use of weight-loss drugs. More specifically, with the first GLP-1 obesity p...
Novo Nordisk (NVO) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview: Novo Nordisk has launched AMAZE 1, a Ph...
Analyst ratings
53%
of 34 ratingsMore NVO News
At the JPMorgan Healthcare Conference, biotechs and Big Pharma signaled they’re primed for M&A this year, after a big year for deals in 2025. Revolution Medici...
Novo Nordisk (NVO) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools...
What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill? If you bought Eli Lilly (LLY 0.35%) shares five years ago, you a...
Danish pharmaceutical giant Novo Nordisk (NVO) is open to big or small deals to bolster its obesity drug portfolio. In an interview with Bloomberg at the JPMorg...
If you are wondering whether Novo Nordisk is fairly priced or if the recent buzz has pushed it too far, this article walks through what the numbers actually say...
Both companies now aim to win in the oral weight loss drug market. Eli Lilly (LLY +0.26%) and Novo Nordisk (NVO 0.68%) have seen revenue climb in recent years...
Key Points Novo Nordisk launched an oral version of its best-selling weight management medicine. It may not help catch up to Eli Lilly, whose oral anti-obesit...
